Search

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 02, 2021
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 23, 2021
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

Press release

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … QR-421a QR-421a is a first-in-class investigational RNA therapy designed to address the underlying cause of vision …

March 25, 2020
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

March 17, 2021
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

February 16, 2021
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

December 11, 2019
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Press release

LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 15, 2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

March 11, 2019
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial

Press release

Key Updates

August 29, 2017
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

Press release

… ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in … to changing lives through the creation of transformative RNA therapies, today announced several presentations at the …

April 26, 2022